Cargando…

CLRM-05. DRUG-RELEASING MICRODEVICES TO PREDICT RESPONSES TO TARGETED THERAPIES IN PATIENTS WITH GLIOMAS

Genomic studies of tumor specimens are becoming standard of care in patients with gliomas to characterize druggable molecular features. Unfortunately, with the exception of IDH1-R132 mutation and MGMT promoter methylation, molecular markers have failed to predict clinical responses to drugs, and the...

Descripción completa

Detalles Bibliográficos
Autores principales:	Blitz, Sarah, Dominas, Christine, Pannell, Michael J, Chiocca, E Antonio, Wen, Patrick Y, Jonas, Oliver, Peruzzi, Pierpaolo
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2021
Materias:	Supplement Abstracts
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8453850/ http://dx.doi.org/10.1093/noajnl/vdab112.004

Ejemplares similares

CLRM-05 FEASIBILITY OF EVALUATING ABEMACICLIB NEUROPHARMACOKINETICS OF DIFFUSE MIDLINE GLIOMA USING INTRATUMORAL MICRODIALYSIS
por: Dalmage, Mahalia, et al.
Publicado: (2022)

CLRM-13. INTRAOPERATIVE MICRODIALYSIS: GLIOMA INTELLIGENCE FROM BEHIND ENEMY LINES
por: Riviere-Cazaux, Cecile, et al.
Publicado: (2021)

Preparation and sterilization of an implantable drug-delivery microdevice for clinical use
por: Dominas, Christine, et al.
Publicado: (2021)

CLRM-14 INTRATUMORAL EXTRACELLULAR METABOLIC IMPACT OF DFMO AND AMXT 1501 IN LIVE HUMAN GLIOMAS
por: Riviere-Cazaux, Cecile, et al.
Publicado: (2022)

CLRM-03 INCIDENCE OF INTRACRANIAL HEMORRHAGE IN GLIOMA PATIENTS WITH VENOUS THROMBOEMBOLISM CONVERTED FROM LMWH TO APIXABAN
por: Aboud, Orwa, et al.
Publicado: (2022)

CLRM-08. TRIAL WORKING GROUPS FOR PAEDIATRIC BRAIN TUMOURS
por: Rahman, Ruman, et al.
Publicado: (2021)

CLRM-20 IDENTIFYING RISK FACTORS AND ANALYZING SURVIVAL FOLLOWING PACHYMENINGEAL FAILURE
por: Kalyvas, Aristotelis, et al.
Publicado: (2022)

CLRM-18 SCREEN FAILURES IN PHASE III GLIOBLASTOMA CLINICAL TRIALS
por: Peters, Katherine
Publicado: (2022)

CLRM-06 PROSPECTIVE CLINICAL STUDY OF CONVENTIONALLY FRACTIONATED CONCURRENT CHEMORADIOTHERAPY AND HYPOFRACTIONATED CONCURRENT CHEMORADIOTHERAPY AFTER THE SURGERY OF HIGH-GRADE GLIOMAS
por: Weiyan, Shi
Publicado: (2022)

CLRM-07 A MULTIVARIATE RETROSPECTIVE ANALYSIS OF 159 PATIENTS WITH HIGH-GRADE GLIOMAS: OVERALL SURVIVAL, PROGRESSION-FREE SURVIVAL, AND PROGNOSTIC FACTORS
por: Liu, Shiyu, et al.
Publicado: (2022)

CLRM-11 CURRENT STATE OF CLINICAL TRIALS FOR PATIENTS WITH MELANOMA BRAIN METASTASES
por: Elghawy, Omar, et al.
Publicado: (2022)

CLRM-01 SUMMARY OF VIRTUAL TUMOR BOARD PLATFORMS AND IMPLEMENTATION IN NEURO-ONCOLOGY
por: Ekhator, Chukwuyem, et al.
Publicado: (2022)

Self-Expanding Anchors for Stabilizing Percutaneously Implanted Microdevices in Biological Tissues
por: Bhagavatula, Sharath, et al.
Publicado: (2021)

CLRM-12. HYBRID DESIGNS FOR USING EXTERNAL CONTROLS IN PHASE 3 GLIOBLASTOMA TRIALS
por: Polley, Mei-Yin, et al.
Publicado: (2021)

CLRM-19 USING FUNCTIONAL PRECISION MEDICINE TO GUIDE CLINICAL TRIAL ENROLLMENT IN GBM
por: Ledford, Aubrey, et al.
Publicado: (2022)

CLRM-01. MACHINE LEARNING TO UNCOVER SIGNATURES OF VULNERABILITY IN GLIOBLASTOMA UMBRELLA SIGNATURE TRIAL (GUST)
por: Peng, Sen, et al.
Publicado: (2021)

CLRM-09. INCORPORATING EXTERNAL CONTROL ARM IN MDNA55 RECURRENT GLIOBLASTOMA REGISTRATION TRIAL
por: Davi, Ruthanna, et al.
Publicado: (2021)

CLRM-11. BENCH TO BEDSIDE NEURO-ONCOLOGY: ADVOCATING FOR A CLINICALLY RELEVANT STRATEGY AS UNDERSCORED BY THE PANDEMIC
por: Brown, Timothy, et al.
Publicado: (2021)

CLRM-17 USE OF EXTERNAL CONTROL DATA FOR PLANNING AND ANALYZING GBM TRIALS: READY FOR PRIME TIME?
por: Polley, Mei-Yin, et al.
Publicado: (2022)

CLRM-03. BGB-290 AND TEMOZOLOMIDE IN TREATING ISOCITRATE DEHYDROGENASE (IDH)1/2-MUTANT GRADE I-IV GLIOMAS – A NOVEL MODEL OF AYA TRIAL DEVELOPMENT AND DEPLOYMENT
por: Marks, Asher, et al.
Publicado: (2021)

FSMP-05. KETOGENIC DIETS FOR HIGH-GRADE GLIOMA
por: Immidisetti, Amanda, et al.
Publicado: (2021)

CLRM-13 RELEVANCE OF RECURSIVE PARTITIONING ANALYSIS (RPA) CLASSIFICATION IN THE CURRENT CARE OF PATIENTS WITH BRAIN METASTASES (BMETS)
por: Sarai, Guneet, et al.
Publicado: (2022)

CLRM-16 PATIENT-FOCUSED DRUG DEVELOPMENT IN NEURO-ONCOLOGY: A PILOT STUDY OF QUALITATIVE PATIENT INTERVIEWS EMBEDDED WITHIN A NEUROFIBROMATOSIS 2 CLINICAL TRIAL
por: Merker, Vanessa, et al.
Publicado: (2022)

CLRM-21 RISK FACTORS ASSOCIATED WITH THE PRESENCE OF BRAIN METASTASIS AT THE MOMENT OF DIAGNOSIS IN LUNG CANCER PATIENTS: RETROSPECTIVE CASE SERIES
por: Martín-Abreu, Carla M, et al.
Publicado: (2022)

A Two-Photon Microimaging-Microdevice System for Four-Dimensional Imaging of Local Drug Delivery in Tissues
por: Liu, Guigen, et al.
Publicado: (2021)

CBMS-05 Biological and Pathological meaning of aneuploidy in mouse glioma stem sell
por: Negoto, Tetsuya, et al.
Publicado: (2020)

CLRM-04. PHASE I/II SAFETY AND EFFICACY STUDY OF BET BROMODOMAIN INHIBITOR OTX-015 WITH OLAPARIB AND LOMUSTINE IN PATIENTS WITH RECURRENT GLIOBLASTOMA
por: Lam, Fred
Publicado: (2021)

CLRM-02 SINGLE CENTER EXPERIENCE OF DOPAMINE ANTAGONIST ONC-201 FOR RECURRENT H3K27M-MUTANT GLIOBLASTOMA IN ADULTS
por: Ekhator, Chukwuyem, et al.
Publicado: (2022)

CLRM-09 FIRST-LINE Tumor TREATING FIELDS (200 KHZ) THERAPY FOR NEWLY-DIAGNOSED GLIOBLASTOMA: THE PHASE 3 TRIDENT TRIAL (EF-32)
por: Shi, Wenyin, et al.
Publicado: (2022)

CLRM-07. INCREASING EFFICIENCY IN EARLY PHASE MULTICENTER IMAGING BIOMARKER TRIALS: EMERGING STRATEGIES FROM THE GABLE (GLIOBLASTOMA ACCELERATED BIOMARKER LEARNING ENVIRONMENT) TRIAL
por: Barboriak, Daniel, et al.
Publicado: (2021)

COT-05 Experience of fertility preservation in 3 male cases and 1 female case with high-grade glioma
por: Nakayama, Noriyuki, et al.
Publicado: (2020)

CLRM-10 METIS (EF-25): A PIVOTAL, RANDOMIZED CONTROLLED STUDY OF TUMOR TREATING FIELDS IN PATIENTS WITH 1–10 BRAIN METASTASES FROM NON-SMALL CELL LUNG CANCER
por: Mehta, Minesh, et al.
Publicado: (2022)

CLRM-10. THE INTER-RELATIONSHIP BETWEEN MULTI-MODAL LONGITUDINAL BIOMARKERS OF NEURAL DAMAGE, INFLAMMATION, AND COGNITION AFTER CAR T CELLULAR THERAPY: A SINGLE-CENTER PROSPECTIVE OBSERVATIONAL TRIAL (NCT04614987)
por: Butt, Omar, et al.
Publicado: (2021)

CLRM-02. TRIAL IN PROGRESS: A PROSPECTIVE, MULTICENTER PHASE 2B STUDY TO ESTABLISH IMAGE INTERPRETATION CRITERIA FOR (18)F-FLUCICLOVINE PET IN DETECTING RECURRENT BRAIN METASTASES AFTER RADIATION THERAPY (PURSUE)
por: Kotecha, Rupesh, et al.
Publicado: (2021)

CLRM-08 TARGETING IMMUNE-PAYLOAD TO THE GLIOBLASTOMA TUMOR MICROENVIRONMENT USING A MACROPHAGE-BASED TREATMENT RELYING ON AUTOLOGOUS, GENETICALLY MODIFIED, HEMATOPOIETIC STEM CELL-BASED THERAPY: THE TEM-GBM STUDY (NCT03866109)
por: Eoli, Marica, et al.
Publicado: (2022)

CLRM-06. COMPARISON OF INDIVIDUALIZED ANTI-CANCER THERAPY REGIMENS RECOMMENDED BY A MULTIDISCIPLINARY MOLECULARLY-DRIVEN TUMOR BOARD IN A PEDIATRIC DIPG CLINICAL TRIAL (PNOC003) VERSUS THOSE SELECTED BY THE CNS-TAP TOOL
por: Roberts, Holly, et al.
Publicado: (2021)

CLRM-12 TITLE: STEREOTACTIC RADIOSURGERY (ADJUVANT OR NEOADJUVANT) COMPARED TO HIPPOCAMPAL AVOIDANCE WHOLE BRAIN RADIATION THERAPY WITH SIMULTANEOUS INTEGRATED BOOST FOR LIMITED BRAIN METASTASES (SRS-CHART): PHASE III OPEN-LABEL PARALLEL-GROUP RANDOMIZED CONTROLLED TRIAL
por: Dasgupta, Archya, et al.
Publicado: (2022)

BIMG-05. TO BE OR NOT TO BE GLYCOLYTIC: DEUTERATED GLUCOSE-BASED ASSESSMENT OF THE WARBURG EFFECT ALLOWS NON-INVASIVE IMAGING OF TUMOR BURDEN AND TREATMENT RESPONSE IN MUTANT IDH GLIOMAS IN VIVO
por: Taglang, Celine, et al.
Publicado: (2021)

BSCI-05 REPURPOSING PROPOFOL FOR THE TREATMENT OF BRAIN METASTASES
por: Penning, Donald, et al.
Publicado: (2022)

Gastrointestinal-resident, shape-changing microdevices extend drug release in vivo
por: Ghosh, Arijit, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_238r45n0jke3b0a7tjtssm9brn